Alliance Partners
Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With a 70-plus-year heritage, Alcon are the largest eye care device company in the world – with complementary businesses in Surgical and Vision Care. Being a truly global company, Alcon works in over 70 countries and serves patients in more than 140 countries. Alcon has a long history of industry firsts, and each year we commit a substantial amount in Research and Development to meet customer needs and patient demands.
ASO and Alcon have been in partnership since 2017.
As a member of Australian Society of Ophthalmologists, upon purchasing a new or demonstrator BMW you are eligible to enjoy the rewards of BMW Advantage Programme.
As a member of the ASO, you are entitled to the following benefits when you purchase a new BMW:
- Complimentary scheduled servicing for 3 years or 60,000km.
- Complimentary use of a BMW during scheduled servicing.
- Reduced Dealer delivery of $1,850 excluding taxes.
- BMW Corporate benefits extended to your spouse.
- Reduced rate on a BMW Driving Experience course.
- 3 years unlimited kilometre warranty.
- Access to BMW Genius.
- BMW Roadside assistance.
- Competitive finance rates across a range of products through BMW Financial Services.
What to do next?
If the idea of driving a new BMW sounds appealing, call the dedicated BMW Corporate Team on 1800 635 750 or email: corporate@bmw.com.au to find out more about the benefits and exclusive offers for members.
Cutcher & Neale specialise in the provision of advisory services for medical practitioners at all stages of their career:
- Doctors in Training (including WealthStartTM, our tailored accounting advisory
package for DITs) - Doctors in private practice
- Visiting medical officers, staff specialists and consultants
- Specialists looking to become practice owners
- Practice owners looking for practice succession solutions
- Medical practitioners planning for their retirement
- Investment advice
- Life, sickness and accident insurance
Established in 1953, our firm today has eight partners and approximately 130 staff. Our expertise is built on an intimate understanding of the unique requirements of the medical profession acquired over more than 65 years.
Cutcher & Neale offers ASO members a complimentary general consultation (telephone or web also available) at Cutcher & Neale’s cost. To book your consultation, phone 1800 988 522 or email medical@cutcher.com.au
We also hold regular seminars and workshops in metropolitan, regional and country NSW.
In 2018, Cutcher & Neale were proud to receive the following accolades:
- Number 36 in the Australian Financial Review Top100 Accounting Firms
- SMSF Firm of the Year (NSW)
- Phil Smith (Partner) – SMSF Investment Strategist of the Year (NSW)
Visit www.cutcher.com.au for more information.
Eye Learning is an online learning company providing online ophthalmic assistant, ophthalmic receptionist, and infection control courses.
These courses are specifically designed to teach ophthalmic knowledge and clinical skills required to work in ophthalmic clinics.
As of 1 July 2023, ASO members enjoy an exclusive 10% discount off all Eye Learning courses.
Glaukos is transforming the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs.
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
We were the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure that revolutionised the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018 and iStent inject® W in September 2020.
In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for glaucoma, corneal health, and retinal diseases.
Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is located in San Clemente, California, and we have additional locations in 9 regions around the world.
At Glaukos, we are dedicated to addressing the greatest unmet needs of the global ophthalmic market, for physicians and for patients. That’s why we’ve spent more than a decade re-investing in R&D and clinical trial programs to develop and advance a deep pipeline of novel therapies currently being evaluated in FDA clinical trials, while leading the industry in clinical support and patient education resources. And it’s why we’re seeking to leverage our platform technologies to build an unrivaled portfolio of next-generation surgical and pharmaceutical therapies in glaucoma, corneal health, and retinal disease.
We’ve achieved many firsts in clinical studies and over the past several years, Glaukos has reinvested approximately 30% of all sales back into research and development activities – all to relentlessly advance our goal of creating and delivering transformative therapies for patients struggling with eye diseases and the skilled surgeons dedicated to their healing.
We’re proud of the corporate citizenship efforts of the Glaukos Charitable Foundation, Company and employees, and pledge to continue this important work in helping improve the lives of those suffering and in need.
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. As a global leader in eye-health, we have a bold ambition: Vision Made Possible – and are paving the way for a new future of eye health to support the full spectrum of paediatric, developed and mature eyes. Through cutting-edge innovation, scientific expertise, and advanced technologies, we are revolutionising the way people see and experience the world. At every step of the eye health journey – from investigational gene therapies for retinal diseases to contact lenses and refractive and cataract surgical solutions – we stand as a trusted partner with the goal of making vision possible for customers and patients.
Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.
MDA National is the ASO’s preferred medical indemnity provider. MDA National is a member owned medical indemnity specialist that exists only to protect and support doctors. We are about being the best for our members at the times that matter most — providing the industry’s best advice, resources and expertise, so you can keep on practicing with confidence and provide the best medical care to your patients.
Whether you’re training or practising as an Ophthalmologist, MDA National’s
medico-legal experts are always there to support you, no matter how big or
small your concerns.
- Individualised advice and support
- Unparalleled member care and expertise
- Benefits tailored to your career stage
Save 12.5% on your Professional Indemnity Insurance
If you’re a member of both the ASO and MDA National, you’ll save 12.5% on your MDA National Professional Indemnity Insurance Premium and Membership
Subscription.*
mdanational.com.au | 1800 011 255 | peaceofmind@mdanational.com.au
^ASO trainee members covered under the MDA National Doctor in Specialist
Training (DiST) category.
*Subject to certain eligibility criteria and underwriting approval.
The MDA National Group is made up of MDA National ABN 67 055 801 771 and MDA National Insurance Pty Ltd (MDA National Insurance) ABN 56 058 271 417 AFS Licence No. 238073. Insurance products are underwritten by MDA National Insurance. Before deciding to buy or hold any products issued by MDA National Insurance, please consider your circumstances, read the Product Disclosure Statement and Policy Wording and any applicable Supplementary Product documentation at mdanational.com.au.
ASO is excited to announce a partnership with Orbit World travel and has secured a range of exclusive benefits for ASO members.
Contact Orbit Travel on our exclusive ASO email: aso@orbitworldtravel.com.au or phone Orbit’s VIP line: 1300 262 885 to find out about their offerings.
